



# Asporelix®

Cetrorelix Acetate 0.25mg




## Cetrorelix Acetate, GnRH-ant for downregulation




**Cetrorelix 0.25mg, a synthetic decapeptide with Gonadotropin Releasing Hormone (GnRH) antagonist activity.**

- **Easy to manage LH suppression<sup>2</sup>**
- **Reduced incidences of OHSS<sup>1</sup>**
- **No flare up effects observed, hence reducing the risk of cyst formation<sup>3,4</sup>**

### Significantly lower OHSS<sup>5</sup>



### Significantly higher Clinical Pregnancy rates observed<sup>6</sup>



## Better Safety & Efficacy Profile as compared to Ganirelix

1. Eftekhar M, et al. JBRA Assist Reprod. 2018;22(3):238-243.

2. Dawood A, et al. Clin Exp Reprod Med. 2017;44(4):232.

3. Felberbaum R, Diedrich K. Reprod Biomed Online. 2003;6(1):43-53.

4. Depalo KR, Jayakrishnan K, et al. Reprod Biol Endocrinol. 2012;10(1):26.

5. Zhang J, Zhou X, Chen Y, Zhang Q, Li Y, Zhe J, Chen X, Chen S. Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles. Nan Fang yi ke da xuexie bao= Journal of Southern Medical University. 2019 Oct 1;39(10):1207-12.

6. Maletta N, Dieterich C, Check JH, Dix E, Brasi le O. The Adverse Effect of Ganirelix Versus Cetrorelix on Pregnancy Rates (PRs) and Implantation Rates Is Not Associated With Midluteal Phase Echo Patterns. Fertility and Sterility. 2008 Apr 1;89(4): S24. OHSS: Ovarian hyperstimulation syndrome.

LH: Luteinizing Hormone.

OHSS: Ovarian Hyperstimulation Syndrome.

#### PRODUCT REGISTRATION HOLDER:

FIRSTLINE PHARMACEUTICALS SDN. BHD. (200301009277) (611697-X)

www.firstline.com.my

info@firstline.com.my

+60 3-7890 3018

#### DISTRIBUTED BY:

ANTAH PHARMA SDN. BHD. (188544-X)

NO.3, JALAN 19/1, 46000 PETALING JAYA

+60 3-7956 7677

